Real‐world re‐treatment outcomes of direct‐acting antiviral therapy failure in patients with chronic hepatitis C-Reference-Cited by-同舟云学术

Real‐world re‐treatment outcomes of direct‐acting antiviral therapy failure in patients with chronic hepatitis C

Published:2021-04-13 Issue:8 Volume:93 Page:4982-4991
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Elhence Anshuman¹,Singh Achintya²,Anand Abhinav¹,Kumar Ramesh³,Ashraf Anzar¹,Kumar Sonu¹,Pradhan Dibyabhaba⁴,Pathak Piyush¹,Vaishnav Manas¹,Rajput Mahendra Singh¹,Banyal Vikas¹,Nayak Baibaswata¹,Shalimar ¹^ORCID

Affiliation:

1. Department of Gastroenterology and Human Nutrition All India Institute of Medical Sciences New Delhi India

2. Department of Internal Medicine Cleveland Clinic Cleveland Ohio USA

3. Department of Gastroenterology All India Institute of Medical Sciences Patna India

4. Indian Council of Medical Research, Computational Genomics Centre All India Institute of Medical Sciences New Delhi India

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26971

Reference21 articles.

1. WHO. Global hepatitis report. 2017.http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed February 16 2020.

2. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection

3. WHO. Global health sector strategy on viral hepatitis 2016‐2021. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. Accessed March 23 2020.

4. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R)

5. Prevention and management of treatment failure to new oral hepatitis C drugs

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of comorbid conditions and prescribed chronic medications on the treatment plan for chronic hepatitis C infection: A cross‐sectional retrospective study;Health Science Reports;2024-04-29

2. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks;2024-04-10

3. Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?;Cost Effectiveness and Resource Allocation;2024-02-06

4. Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs;Journal of Clinical and Experimental Hepatology;2023-09

5. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks;Journal of Clinical Virology Plus;2023-06